The Effect of Fatty Liver On Hepatic Gene Expression and Protein Activity



What is the purpose of this trial?

Hypothesis 1. In patients with T2DM, as compared to nondiabetic controls, increased hepatic glucose production from hepatic gluconeogenesis is associated with increased transcription of gluconeogenic enzymes. Hypothesis 2. In patients with NAFLD, the accumulation of diacylglycerol (DAG) will be associated with increased activation of a novel protein kinase C isoform and hepatic insulin resistance. Hypothesis 3. Roux-en-Y gastric bypass (RYGB), but not gastric banding, will lead to rapid reductions in hepatic lipid content and improvements in hepatic insulin sensitivity. Hypothesis 4: Subjects with polymorphisms in ApoC3 who have increased liver content, will have accumulation of the fatty acid, DAG, and hepatic insulin resistance. Subjects with polymorphisms in PNPLA3, who have fatty liver, will have increased in other fat species than DAG and therefore have normal hepatic insulin action.

Participation Guidelines

18 Years - 65 Years

Click here for detailed information about who can participate in this trial.

National Institutes of Health
Last Updated:
Study HIC#: